Related Experiment Video

Updated: Jul 17, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of

J Robert Swenson1, Steve Doucette, Dean Fergusson

  • 1Department of Psychiatry, University of Ottawa, Ontario. jrswenson@ottawahospital.on.ca

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|January 26, 2007
PubMed
Abstract

Insights

Selective serotonin reuptake inhibitors (SSRIs) did not show a clear cardiovascular risk in high-risk patients. More research is needed due to limited data and reporting in trials.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants.
  • Patients with pre-existing cardiovascular conditions or risk factors may be prescribed SSRIs.
  • The cardiovascular safety of SSRIs in these high-risk populations requires thorough investigation.

Purpose of the Study:

  • To systematically review randomized controlled trials to assess the risk of cardiovascular adverse events (AEs) associated with SSRI use.
  • To compare cardiovascular AE rates between SSRIs, tricyclic antidepressants (TCAs), other active therapies, and placebo in high-risk patients.

Main Methods:

  • Systematic review of randomized controlled trials (1967-May 2005).
  • Inclusion of patients with cardiac disease, diabetes, stroke, advanced age, substance dependence, or obesity.
  • Defined serious AEs (cardiac death, heart failure, stroke, MI) and nonserious AEs (palpitations, chest pain, etc.).

Main Results:

  • Stroke and cardiac patients faced the highest risk for cardiovascular AEs.
  • No significant difference in serious or nonserious AEs between SSRIs and placebo was detected.
  • SSRIs showed a significant reduction in nonserious AEs compared to TCAs (OR 0.46; 95% CI, 0.24-0.86).

Conclusions:

  • This review could not definitively establish whether SSRIs increase or decrease cardiovascular AE risk in high-risk patients.
  • Rarity of serious AEs, insufficient trial sizes, and inadequate reporting hindered definitive conclusions.
  • Further trials with robust reporting of cardiovascular AEs are necessary to clarify SSRI safety in these populations.

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...